Study of Ivonescimab for advanced skin or prostate cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either advanced skin cancer (that can't be surgically removed or has spread) OR advanced prostate cancer that's no longer responding to hormone therapy.
- If you have skin cancer, you must have already tried or not had a type of immunotherapy called anti-PD-1 (like Keytruda or Opdivo).
- You are in generally good health, with good kidney, liver, and blood function.
- You do not have an active autoimmune disease, serious infection, or HIV/hepatitis.
- You have not had another cancer that is growing or needs treatment, except for some minor skin cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.